Skip to main content

Developing A NextGen RNA Therapy for Rett Syndrome

December 16, 2020

David Huss, PhD, VP, Head of Research for Shape Therapeutics discusses the company's proprietary RNA technologies and how they will be applied to fix MECP2 mutations, the root cause of Rett syndrome.


More Resources

Our Plan for a Cure: RNA Editing

Our Plan for a Cure: RNA Trans-Splicing